Humira Biosimilar Interchangeability: The Race Begins
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.